Sökning: WFRF:(Warsi Sarah) > Organ sparing total...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04777naa a2200457 4500 | |
001 | oai:lup.lub.lu.se:01cb8053-60dd-415a-9160-a31b249d1413 | |
003 | SwePub | |
008 | 210716s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/01cb8053-60dd-415a-9160-a31b249d14132 URI |
024 | 7 | a https://doi.org/10.1111/ejh.136752 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Haraldsson, Andréu Lund University,Lunds universitet,Medicinsk strålningsfysik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Radiotherapy Physics,Forskargrupper vid Lunds universitet,Medical Radiation Physics, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)an3320ha |
245 | 1 0 | a Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation |
264 | c 2021-06-24 | |
264 | 1 | b Wiley,c 2021 |
520 | a Objectives: Total body irradiation (TBI) is commonly used prior to hematopoietic stem cell transplantation (HSCT) in myeloablative conditioning regimens. However, TBI may be replaced by total marrow irradiation (TMI) at centres with access to Helical TomoTherapy, a modality that has the advantage of delivering intensity-modulated radiotherapy to long targets such as the entire bone marrow compartment. Toxicity after organ sparing TMI prior to HSCT has not previously been reported compared to TBI or with regard to engraftment data. Methods: We conducted a prospective observational study on 37 patients that received organ sparing TMI prior to HSCT and compared this cohort to retrospective data on 33 patients that received TBI prior to HSCT. Results: The 1-year graft-versus-host disease-free, relapse-free survival (GRFS) was 67.5% for all patients treated with TMI and 80.5% for patients with matched unrelated donor and treated with TMI, which was a significant difference from historical data on TBI patients with a hazard ratio of 0.45 (P =.03) and 0.24 (P <.01). Engraftment with a platelet count over 20 [K/µL] and 50 [K/µL] was significantly shorter for the TMI group, and neutrophil recovery was satisfactory in both treatment cohorts. There was generally a low occurrence of other treatment-related toxicities. Conclusions: Despite small cohorts, some significant differences were found; TMI as part of the myeloablative conditioning yields a high 1-year GRFS, fast and robust engraftment, and low occurrence of acute toxicity. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a ALL | |
653 | a HSCST | |
653 | a TBI | |
653 | a TMI | |
653 | a Tomotherapy | |
700 | 1 | a Wichert, Stinau Skåne University Hospital4 aut0 (Swepub:lu)med-swt |
700 | 1 | a Engström, Per E.u Skåne University Hospital4 aut0 (Swepub:lu)med-pre |
700 | 1 | a Lenhoff, Stigu Skåne University Hospital4 aut0 (Swepub:lu)med-slf |
700 | 1 | a Turkiewicz, Dominiku Skåne University Hospital4 aut0 (Swepub:lu)do8070tu |
700 | 1 | a Warsi, Sarahu Lund University,Lunds universitet,Avdelningen för molekylärmedicin och genterapi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Hematopoes och genterapi,Forskargrupper vid Lunds universitet,Division of Molecular Medicine and Gene Therapy,Department of Laboratory Medicine,Faculty of Medicine,Hematopoiesis and Gene Therapy,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)med-swr |
700 | 1 | a Engelholm, Silkeu Skåne University Hospital4 aut |
700 | 1 | a Bäck, Svenu Lund University,Lunds universitet,Medicinsk strålningsfysik, Malmö,Forskargrupper vid Lunds universitet,Radiotherapy Physics,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Medical Radiation Physics, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)rfa-sba |
700 | 1 | a Engellau, Jacobu Skåne University Hospital4 aut0 (Swepub:lu)onk-jen |
710 | 2 | a Medicinsk strålningsfysik, Lundb Sektion V4 org |
773 | 0 | t European Journal of Haematologyd : Wileyg 107:4, s. 393-407q 107:4<393-407x 0902-4441x 1600-0609 |
856 | 4 | u http://dx.doi.org/10.1111/ejh.13675x freey FULLTEXT |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13675 |
856 | 4 8 | u https://lup.lub.lu.se/record/01cb8053-60dd-415a-9160-a31b249d1413 |
856 | 4 8 | u https://doi.org/10.1111/ejh.13675 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy